Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.8692 +0.0299 (+3.56%)
Streaming Delayed Price Updated: 11:15 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amarin Corp ADR

< Previous 1 2 3 4 5 Next >
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Analyzing Amarin Corp's Unusual Options Activity
Shares of Amarin Corp (NASDAQ:AMRN) saw some unusual opti... 
Via Benzinga
Analyzing Amarin Corp's Unusual Options Activity
Shares of Amarin Corp (NASDAQ:AMRN) saw some unusual opti... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Lower Vascepa Volume Hits Amarin's Q4 Topline Growth
Amarin Corp plc's (NASDAQ: AMRN) Q4 FY21 sales decreased 13.6% Y/Y to $144.49 million, beating the consensus of $141.75 million. The decline was driven primarily by... 
Via Benzinga
Amarin: Q4 Earnings Insights
Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're starting off the day right with a dive into the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
Why Amarin Stock Tumbled in November
The biopharma's stock could be near a bottom after last month's double-digit decline. 
Via The Motley Fool
Why Amarin Stock Crushed the Market on Tuesday
An activist investor revealed that it held a small stake in the company. 
Via The Motley Fool
Amarin Posts Encouraging Vascepa Data In Patients With Peripheral Artery Disease
Amarin Corporation plc (NASDAQ: AMRN) reported new data for Vascepa/Vazkepa (icosapent ethyl) at the American Heart Association (AHA) Scientific Sessions. The... 
Via Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Amarin (AMRN) Q3 2021 Earnings Call Transcript
AMRN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Cramer Shares His Thoughts On Dynavax, Nucor And Amarin
On CNBC's "Mad Money Lightning Round," Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX) is good. He loves the immuno drug stories. Cramer said you are... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
Amarin Stock Moves Higher As Vascepa Cuts Risk Of Heart Attacks
Amarin Corporation plc (NASDAQ: AMRN) announced additional data on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack, known as myocardial... 
Via Benzinga
Why Amarin Is Soaring Today
The pharmaceuticals company is showing surprising resilience in the face of competition. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
77 Biggest Movers From Yesterday
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company announced it is expanding its blockchain business to... 
Via Benzinga
Amarin (AMRN) Q2 2021 Earnings Call Transcript
AMRN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Amarin Q2 Earnings
Shares of Amarin Corp (NASDAQ:AMRN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the... 
Via Benzinga
Understanding Amarin Corp's Unusual Options Activity
Shares of Amarin Corp (NASDAQ:AMRN) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $4.22. Sentiment: BEARISH Option... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.